NASDAQ:SRDX Surmodics (SRDX) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free SRDX Stock Alerts $29.61 +0.81 (+2.81%) (As of 11:48 AM ET) Add Compare Share Share Today's Range$29.18▼$29.6150-Day Range$27.44▼$35.5652-Week Range$16.79▼$39.41Volume13,657 shsAverage Volume41,284 shsMarket Capitalization$421.65 millionP/E Ratio77.92Dividend YieldN/APrice Target$59.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Surmodics alerts: Email Address Surmodics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.9% Upside$59.00 Price TargetShort InterestBearish3.24% of Float Sold ShortDividend StrengthN/ASustainability-2.52Upright™ Environmental ScoreNews Sentiment0.61Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.90) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.36 out of 5 starsMedical Sector135th out of 939 stocksSurgical & Medical Instruments Industry17th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingSurmodics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.00, Surmodics has a forecasted upside of 104.9% from its current price of $28.80.Amount of Analyst CoverageSurmodics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.24% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Surmodics has recently decreased by 1.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSurmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Surmodics is -2.52. Previous Next 2.6 News and Social Media Coverage News SentimentSurmodics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Surmodics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Surmodics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Surmodics is held by insiders.Percentage Held by Institutions96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Surmodics are expected to grow in the coming year, from ($0.90) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is 75.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is 75.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 180.19.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Surmodics Stock (NASDAQ:SRDX)Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Read More SRDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRDX Stock News HeadlinesMarch 23, 2024 | finance.yahoo.comShould You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?March 23, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Lowered by Zacks ResearchMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 22, 2024 | americanbankingnews.comZacks Research Research Analysts Boost Earnings Estimates for Surmodics, Inc. (NASDAQ:SRDX)March 2, 2024 | finance.yahoo.comAre Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?February 27, 2024 | businesswire.comSurmodics to Participate in Upcoming Investor Conferences in March and AprilFebruary 6, 2024 | ca.finance.yahoo.comSYK Jun 2024 290.000 putFebruary 4, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter ResultsMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…February 2, 2024 | finance.yahoo.comHere's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay PacketFebruary 2, 2024 | finance.yahoo.comSurmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call TranscriptFebruary 2, 2024 | finance.yahoo.comSurmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 ViewFebruary 1, 2024 | marketwatch.comSurmodics Shares Decline 10% on Investors' Lofty Expectations for SurVeilFebruary 1, 2024 | finance.yahoo.comSurmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024February 1, 2024 | msn.comSurmodics beats top-line and bottom-line estimates; updates FY24 outlookFebruary 1, 2024 | finance.yahoo.comSurModics (SRDX) Reports Break-Even Earnings for Q1February 1, 2024 | finance.yahoo.comSurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesFebruary 1, 2024 | finance.yahoo.comSurmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceJanuary 31, 2024 | benzinga.comA Preview Of Surmodics's EarningsJanuary 22, 2024 | finance.yahoo.comSurmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the KneeJanuary 16, 2024 | finance.yahoo.comSurmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1January 10, 2024 | finance.yahoo.comReturns Are Gaining Momentum At Surmodics (NASDAQ:SRDX)January 8, 2024 | finance.yahoo.comSurmodics, Inc. (SRDX) Stock Historical Prices & Data - Yahoo FinanceDecember 14, 2023 | finance.yahoo.comSurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock?November 16, 2023 | finance.yahoo.comSurmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposiumNovember 16, 2023 | finance.yahoo.comSurmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH SymposiumNovember 15, 2023 | finance.yahoo.comSurmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 91% Above Its Share PriceSee More Headlines Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/06/2023Today3/28/2024Next Earnings (Estimated)4/24/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:SRDX CUSIP86887310 CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees376Year Founded1979Price Target and Rating Average Stock Price Target$59.00 High Stock Price Target$71.00 Low Stock Price Target$47.00 Potential Upside/Downside+104.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.38 Trailing P/E Ratio75.79 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,540,000.00 Net Margins3.99% Pretax Margin7.07% Return on Equity8.06% Return on Assets5.11% Debt Debt-to-Equity Ratio0.24 Current Ratio4.84 Quick Ratio3.97 Sales & Book Value Annual Sales$132.58 million Price / Sales3.09 Cash Flow$0.80 per share Price / Cash Flow35.98 Book Value$8.48 per share Price / Book3.40Miscellaneous Outstanding Shares14,240,000Free Float12,969,000Market Cap$410.11 million OptionableOptionable Beta1.01 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Gary R. Maharaj (Age 61)CEO, President & Director Comp: $1.33MMr. Timothy J. Arens (Age 57)Senior VP of Finance & Information Technology and CFO Comp: $645.3kMr. Gordon S. Weber (Age 61)Senior VP of Legal, General Counsel & Secretary Comp: $602.84kMr. Charles W. Olson (Age 60)Senior VP & President of Medical Device Coatings Comp: $618.47kMs. Teryl L. W. Sides (Age 54)Senior VP & President of Vascular Interventions Comp: $744.38kMr. John D. Manders (Age 43)Corporate Controller, VP of Finance & Principal Accounting Officer Mr. Joseph J. Stich (Age 59)Senior VP of Human Resources & President of In Vitro Diagnostics Comp: $570.92kMore ExecutivesKey CompetitorsOrthofix MedicalNASDAQ:OFIXAccurayNASDAQ:ARAYAngioDynamicsNASDAQ:ANGOCytosorbentsNASDAQ:CTSOIntersect ENTNASDAQ:XENTView All CompetitorsInstitutional OwnershipQuadrature Capital LtdBought 13,856 shares on 3/25/2024Ownership: 0.097%Vanguard Group Inc.Bought 13,123 shares on 3/11/2024Ownership: 6.034%Goldman Sachs Group Inc.Sold 12,542 shares on 3/1/2024Ownership: 0.353%Gamco Investors INC. ET ALSold 2,300 shares on 2/15/2024Ownership: 0.508%Citadel Advisors LLCSold 100 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions SRDX Stock Analysis - Frequently Asked Questions Should I buy or sell Surmodics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRDX shares. View SRDX analyst ratings or view top-rated stocks. What is Surmodics' stock price target for 2024? 2 Wall Street analysts have issued 1 year target prices for Surmodics' stock. Their SRDX share price targets range from $47.00 to $71.00. On average, they anticipate the company's stock price to reach $59.00 in the next year. This suggests a possible upside of 104.9% from the stock's current price. View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts. How have SRDX shares performed in 2024? Surmodics' stock was trading at $36.35 on January 1st, 2024. Since then, SRDX shares have decreased by 20.8% and is now trading at $28.80. View the best growth stocks for 2024 here. When is Surmodics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our SRDX earnings forecast. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) issued its quarterly earnings results on Monday, February, 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.13. The firm had revenue of $24.93 million for the quarter, compared to the consensus estimate of $24.19 million. Surmodics had a trailing twelve-month return on equity of 8.06% and a net margin of 3.99%. During the same quarter in the prior year, the company posted ($0.13) earnings per share. What ETF holds Surmodics' stock? Invesco Nasdaq Future Gen 200 ETF holds 1,909 shares of SRDX stock, representing 0.85% of its portfolio. What guidance has Surmodics issued on next quarter's earnings? Surmodics updated its FY 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of -1.170--0.870 for the period, compared to the consensus earnings per share estimate of -1.160. The company issued revenue guidance of $113.0 million-$117.0 million, compared to the consensus revenue estimate of $119.3 million. What is Gary Maharaj's approval rating as Surmodics' CEO? 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX). Who are Surmodics' major shareholders? Surmodics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.04%), Vanguard Group Inc. (6.03%), Dimensional Fund Advisors LP (2.64%), Salem Investment Counselors Inc. (0.91%), Charles Schwab Investment Management Inc. (0.78%) and Nuveen Asset Management LLC (0.62%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr. View institutional ownership trends. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SRDX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.